{
    "clinical_study": {
        "@rank": "107520", 
        "acronym": "SONIA1", 
        "arm_group": [
            {
                "arm_group_label": "no treatment", 
                "arm_group_type": "No Intervention", 
                "description": "comparrator"
            }, 
            {
                "arm_group_label": "Nitisinone 1mg", 
                "arm_group_type": "Experimental", 
                "description": "interventional"
            }, 
            {
                "arm_group_label": "Nitisinone 2mg", 
                "arm_group_type": "Experimental", 
                "description": "interventional"
            }, 
            {
                "arm_group_label": "Nitisinone 4mg", 
                "arm_group_type": "Experimental", 
                "description": "interventional"
            }, 
            {
                "arm_group_label": "Nitisinone 8mg", 
                "arm_group_type": "Experimental", 
                "description": "interventional"
            }
        ], 
        "brief_summary": {
            "textblock": "SONIA 1 is an international, multicentre, randomised, open-label, no-treatment controlled,\n      parallel group, dose-response study to investigate the effect of once daily nitisinone on\n      24-hour urinary homogentisic acid excretion in patients with alkaptonuria after 4-weeks\n      treatment. They study will identify the optimal dose to decrease urine homogentisic acid to\n      near normal levels."
        }, 
        "brief_title": "Dose Response Study of Nitisinone in Alkaptonuria", 
        "completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Alkaptonuria", 
        "condition_browse": {
            "mesh_term": [
                "Alkaptonuria", 
                "Ochronosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria\n\n        A subject must fulfil the following criteria in order to be included in the study:\n\n          1. Diagnosis of alkaptonuria verified by documented elevated urinary homogentisic acid\n             excretion.\n\n          2. Age \u226518 years.\n\n          3. Willing and able to visit the investigational site for study visits.\n\n          4. Signed written informed consent obtained.\n\n        Exclusion criteria\n\n        The presence of any of the following will exclude a subject from inclusion in the study:\n\n          1. Non-alkaptonuria causes of ochronosis.\n\n          2. Currently pregnant or lactating.\n\n          3. Known allergy to nitisinone or any of the constituents of the investigational\n             product.\n\n          4. Use of a protein-restricted diet\n\n          5. Dietary habits or use of homeopathic therapies that interfere with tyrosine\n             catabolism.\n\n          6. Current keratopathy, contact lens use or uncontrolled glaucoma.\n\n          7. Current malignancy.\n\n          8. Uncontrolled hypertension (blood pressure greater than 180 systolic or greater than\n             95 diastolic).\n\n          9. Electrocardiogram changes indicative of myocardial infarction, arrhythmia,\n             tachycardia, bradycardia, left bundle branch block.\n\n         10. Chest radiographic abnormalities, including an infiltrative, mass, congestive heart\n             failure, embolism, atelectasis.\n\n         11. Serum potassium < 3.0 mmol/L.\n\n         12. eGFR < 60 mL/min.\n\n         13. Any hepatic enzymes greater than 3 x upper limit of normal.\n\n         14. Haemoglobin < 10.0 g/dL.\n\n         15. Platelets less than 100 x 109/L.\n\n         16. WBC less than 3.0 x 109/L.\n\n         17. ESR greater than 100 mm/h.\n\n         18. History of alcohol or drug abuse.\n\n         19. Participation in another clinical trial within 3 months of randomisation.\n\n         20. Treatment with nitisinone within 3 months of randomisation\n\n         21. Psychiatric illness or neurological disease that interferes with compliance or\n             communication with health care personnel.\n\n         22. Any other medical condition which in the opinion of the investigator makes the\n             subject unsuitable for inclusion.\n\n         23. Foreseeable inability to cooperate with given instructions or study procedures."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 5, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01828463", 
            "org_study_id": "UoL000928"
        }, 
        "intervention": {
            "arm_group_label": [
                "Nitisinone 1mg", 
                "Nitisinone 2mg", 
                "Nitisinone 4mg", 
                "Nitisinone 8mg"
            ], 
            "description": "doses 1, 2, 4 & 8 mg plus no treatment arm", 
            "intervention_name": "Nitisinone", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Nitisinone"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "August 8, 2013", 
        "location": {
            "contact": {
                "email": "helen.bygott@rlbuht.nhs.uk", 
                "last_name": "Helen Bygott", 
                "phone": "0151 706 4197"
            }, 
            "facility": {
                "address": {
                    "city": "Liverpool", 
                    "country": "United Kingdom", 
                    "state": "Merseyside", 
                    "zip": "L7 8XP"
                }, 
                "name": "Royal Liverpool Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "5", 
        "official_title": "An International, Multicentre, Randomised, Open-label, No-treatment Controlled, Parallel-group, Dose-response Study to Investigate the Effect of Once Daily Nitisinone on 24-hour Urinary Homogentisic Acid Excretion in Patients With Alkaptonuria After 4 Weeks Treatment.", 
        "overall_official": {
            "affiliation": "Royal Liverpool & Broadgreen University Hospitals NHS Truts", 
            "last_name": "L Ranganath", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "dose of nitisinone that decreases urinary homogentisic acid to near normal", 
            "safety_issue": "No", 
            "time_frame": "4 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01828463"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Liverpool", 
            "investigator_full_name": "Professor Lakshminarayan Ranganath", 
            "investigator_title": "Consultant in Metabolic medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "University of Liverpool", 
        "sponsors": {
            "collaborator": {
                "agency": "Royal Liverpool and Broadgreen University Hospitals NHS Trust", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "University of Liverpool", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}